Studies outlines novel strategies for detecting cancer and minimal residual disease

The latest special issue of PLOS Medicine features five studies outlining novel strategies for detecting cancer and for identifying minimal residual disease-; when a small number of tumor cells survive treatment, potentially leading to recurrence of cancer. The studies were selected by PLOS Medicine's editorial team and guest editors Chris Abbosh, Sarah-Jane Dawson, and Charles Swanton.

Last year, more than 19 million people around the world were newly diagnosed with cancer, and more than 10 million died from the disease. The ability to detect cancer early and to identify minimal residual disease could help improve timely treatment and lower these numbers.

Two of the featured studies discuss innovations in early detection. One, led by Jeffrey Szymanski of Washington University School of Medicine, United States demonstrates the potential for an approach called plasma cell-free DNA ultra-low-pass whole-genome sequencing to distinguish between benign and malignant tumors caused by the condition neurofibromatosis type 1-; and to help monitor the effectiveness of treatment.

The other, led by Brian Nicholson of the University of Oxford, UK outlines how routine clinical tests could be widely used to estimate the risk of cancer for people with unexpected weight loss.

The other three studies address minimal residual disease. Yaqi Wang of Fudan University Shanghai Cancer Center, China, and colleagues showed that combining magnetic resonance imaging with measurements of circulating tumor DNA (ctDNA)-; tumor DNA found in the bloodstream-; can help predict treatment effectiveness and risk of recurrence for people with locally advanced rectal cancer.

Meanwhile, Jeanne Tie of the Walter and Eliza Hall Institute of Medical Research, Australia, and colleagues demonstrated that post-treatment ctDNA measurements can help predict the risk of relapse for people with colorectal cancer that has spread to the liver.

Lastly, Pradeep Chauhan of Washington University School of Medicine, the United States, and colleagues showed how next-generation sequencing of tumor DNA found in urine could aid in detecting minimal residual disease and guide personalized treatment for people with bladder cancer that has invaded the bladder wall.

The methods outlined in all five studies have the potential to be widely applied and could help inform the future of cancer care and research.

Journal reference:

Chauhan, P. S., et al. (2021) Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. PLoS Medicine.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Active commuters less likely to suffer from heart disease and cancer, new research shows